Aetna Cabazitaxel (Jevtana) Coverage Policy Update — CPB 0806 (2026)

Aetna, a CVS Health company, has modified CPB 0806, its clinical policy bulletin governing cabazitaxel (Jevtana) coverage for metastatic castration-resistant prostate cancer (CRPC). The updated policy, effective March 13, 2026, expands the prior-treatment eligibility pathway to include novel hormone therapies alongside docetaxel-containing regimens—a meaningful shift for oncology practices treating patients who never received docetaxel. If your billing or clinical team is seeking prior authorization for J9043 or J9064, here's exactly what you need to know.

Field	Detail
Payer	Aetna
Policy	Cabazitaxel (Jevtana) — CPB 0806
Policy Code	CPB 0806
Change Type	Modified
Effective Date	2026-03-13
Impact Level	High
Specialties Affected	Medical Oncology, Urology, Hematology-Oncology, RCM/Oncology Billing
Key Action	Update prior auth documentation to include novel hormone therapy history (enzalutamide, abiraterone) as a qualifying prior-treatment pathway for cabazitaxel approval.

What Changed in Aetna's Cabazitaxel Policy CPB 0806

The most significant modification in this update is the explicit addition of novel hormone therapy (NHT) as a qualifying prior-treatment pathway for cabazitaxel medical necessity. Previously, the policy centered on docetaxel exposure as the primary treatment history requirement.

Under the revised CPB 0806, Aetna now considers cabazitaxel medically necessary for metastatic CRPC when a member has been previously treated with either:

A docetaxel-containing regimen—or when the member is not a candidate for, or is intolerant to, docetaxel; or
A novel hormone therapy, specifically citing enzalutamide (Xtandi) or abiraterone (Zytiga) as examples.

This is clinically significant. In real-world oncology practice, a growing number of mCRPC patients receive abiraterone or enzalutamide before any taxane chemotherapy. Under the previous framing of this policy, those patients could face authorization friction. The updated language removes that ambiguity and creates a direct pathway for NHT-pretreated patients.

Aetna Cabazitaxel Medical Necessity Criteria: Full Breakdown

Metastatic Castration-Resistant Prostate Cancer (CRPC)

Aetna considers cabazitaxel medically necessary for metastatic CRPC patients who meet either of the prior-treatment criteria above. Importantly, the policy also covers patients who are not candidates for or intolerant to docetaxel—meaning you don't need docetaxel treatment history if there's documented clinical contraindication or intolerance.

The second covered indication is metastatic castration-resistant small cell/neuroendocrine prostate cancer. This is a distinct histologic subtype, and Aetna covers cabazitaxel for these patients regardless of prior hormone therapy sequencing.

What Aetna Will Not Cover

Aetna explicitly designates all other indications for cabazitaxel as:

#	Covered Indication
1	Not medically necessary, or
2	Experimental, investigational, or unproven

This means off-label use outside of metastatic CRPC or small cell/neuroendocrine prostate cancer will not be covered, and claims submitted for those indications will be denied. Document your diagnosis codes carefully—C61 (Malignant neoplasm of prostate) is the relevant ICD-10 for standard mCRPC cases.

Continuation of Therapy

Aetna will continue to authorize cabazitaxel for approved indications as long as there is no evidence of unacceptable toxicity or disease progression. Continuation authorizations should include documentation that the patient is tolerating therapy and showing clinical stability or response. Progression or significant toxicity triggers re-evaluation of medical necessity.

Sample Version Diff Line-by-line changes

-Previous Version
+Current Version
-Coverage is considered experimental and investigational for all indications
+Coverage is considered medically necessary when specific criteria are met
-Prior authorization is not required
+Prior authorization is required for initial treatment
 Documentation must include clinical history
-Re-review every 24 months
+Re-review every 12 months with updated clinical documentation

+ 1 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Affected Codes

Covered HCPCS Codes (when selection criteria are met)

Code	Type	Description
J9043	HCPCS	Injection, cabazitaxel, 1 mg
J9064	HCPCS	Injection, cabazitaxel (Sandoz), not therapeutically equivalent to J9043, 1 mg

Note: J9043 and J9064 are not therapeutically equivalent per this policy. If your practice is dispensing the Sandoz biosimilar formulation, bill J9064—do not substitute J9043, as this creates claim discrepancies.

Chemotherapy Administration CPT Codes

Code	Type	Description
96413	CPT	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance
96415	CPT	Chemotherapy administration, intravenous infusion technique; each additional hour

Cabazitaxel infusions typically run longer than one hour. Bill 96413 for the first hour and 96415 for each subsequent hour. Confirm your infusion documentation captures start and stop times to support each unit of 96415.

Related Drug Codes Referenced in Policy (Prior Treatment Documentation)

Code	Type	Description
J9171	HCPCS	Docetaxel, 1 mg IV (prior treatment regimen reference)
J9172	HCPCS	Injection, docetaxel (Ingenus), not therapeutically equivalent to J9171, 1 mg
J9174	HCPCS	Injection, docetaxel (Beizray), 1 mg

These docetaxel codes may appear in a member's prior claims history and serve as supporting documentation that a docetaxel-containing regimen was previously administered.

Related ICD-10 Diagnosis Codes

Code	Description
C61	Malignant neoplasm of prostate
C00.0–C60.9, C62.00–C96.9	Neoplasms (excluding malignant neoplasm of prostate)

For metastatic CRPC, C61 is your primary diagnosis code. Ensure staging and metastatic status are documented in the medical record to support medical necessity for both initial and continuation authorizations.

What Your Billing Team Should Do

#	Action Item
1	Update your prior auth checklists immediately. For any cabazitaxel authorization request submitted to Aetna after March 13, 2026, include documentation of prior novel hormone therapy (abiraterone or enzalutamide) as a standalone qualifying pathway—not just docetaxel history. Pull prior claims for J9171, J9172, J9174 (docetaxel) or any NHT medications from the patient's claims record to attach as supporting documentation.
2	Flag active patients with NHT-only treatment histories. Run a report of current mCRPC patients on your panel who have received abiraterone or enzalutamide but no prior docetaxel. These patients now have a clearer authorization pathway under CPB 0806—if cabazitaxel is clinically appropriate, don't delay pursuing auth on the assumption that docetaxel history is required.
3	Verify the correct HCPCS code before billing. Confirm whether your pharmacy is dispensing the reference product (J9043) or the Sandoz formulation (J9064). Billing the wrong code—even for the same drug class—can trigger a claim mismatch and delay reimbursement.
4	Document docetaxel intolerance or contraindication explicitly. If a patient was never treated with docetaxel due to clinical reasons rather than NHT sequencing, include a physician attestation of ineligibility or intolerance in the prior auth package. Aetna's policy covers this scenario, but the documentation burden is on your team to make it clear.
5	Set continuation auth reminders. Aetna requires that continuation authorizations demonstrate no unacceptable toxicity and no disease progression. Build a workflow—ideally tied to your oncology EHR—to generate continuation auth requests with updated clinical notes before the current authorization period expires.

+ 2 more action items